DIRS.INFO The most relevant business & tech news

☆ 12 portfolio companies report earnings in the week ahead. What we want to hear from each
▼ + stars: | 2024-04-27 | by ( Zev Fima | ) www.cnbc.com time to read: +15 min

The action quickly and sharply reversed back to the upside Friday after blowout earnings reports from Alphabet and Microsoft . In the week ahead, earnings are likely to drive the action again, though we'll get a few important macroeconomic reports. Earnings: We've got the biggest week of the earnings season ahead of us, with 12 Club holdings set to report. Eli Lilly 's report Tuesday morning continues to be all about sales of type-2 diabetes treatment Mounjaro and weight-loss drug Zepbound. In DuPont 's report Wednesday morning, we're looking for a continued rebound in its semiconductor business following a sequential increase last quarter.

Persons: Ford, we'll, Dow Jones, We've, Buckle, Eaton, Eli Lilly, Lilly, We're, Estee Lauder, Fabrizio Freda, we've, Linde, Bausch, Royal Philips, Woodward, SIRI, Archer, Johnson, Stanley Black, Decker, BAX, Cardinal Health, Parker, Belden, Jim Cramer's, Jim Cramer, Jim Organizations: Nasdaq, Microsoft, Meta, Google Search, Big Tech, Nvidia, Broadcom, Ford Motor, Honeywell, Danaher, Labor Department, Labor, PMI, Services PMI, GE Healthcare, Amazon Web Services, Starbucks, Deutsche Bank, DuPont, Bausch Health, U.S ., Appeals, Apple, iPhones, Vision, ON Semiconductor, Resource Partners, Franklin Resources, Paramount, Transocean Ltd, Semiconductors, Arch Capital, Logitech International, Lattice Semiconductor, F5 Networks, Sanmina Corporation, GE HealthCare, PayPal, 3M Company, McDonalds, Enterprise Products Partners, Cola Company, Melco Resorts, Entertainment, SiriusXM Holdings, Oatly, American Electric Power Company, Leidos Holdings, Marathon Petroleum, Daniels, Midland Co, Equitrans Midstream Corporation, HSBC Holdings, HSBC, Devices, Caesars Entertainment, Lumen Technologies, Mondelez, Pfizer, CVS Health, Barrick, Mastercard Inc, Cruise Line Holdings Ltd, Kraft Heinz Company, Marriott International, Ares, Generac Holdings, Johnson Controls, Cenovus Energy Inc, Qualcomm, Devon Energy, Paycom, Axcelis Technologies, Coeur D'Alene Mines, Sunnova Energy International, MGM Resorts International, MGM, Solar Inc, Oil, Allstate, Co, Tenable Holdings, Enovix Corporation, Gladstone Capital, Avis Budget Group, eBay, EBAY, LIN, Novo Nordisk, Natural Resources, PENN Entertainment, Apache, ConocoPhillips, InMode Ltd, Baxter International, Cardinal, Regeneron Pharmaceuticals, Apollo Global Management, LLC, Cinemark Inc, Dominion Energy, Coterra Energy, Coinbase, Bill.com Holdings, Booking Holdings, United States Steel, AXT Inc, Materials, Energy, Hershey Company, XPO Logistics, Cboe, American Pipeline, Amneal Pharmaceuticals, Brookfield Business Partners, Brookfield Renewable Corporation, Magna International, Jim Cramer's Charitable, CNBC, Traders, New York Stock Exchange, Bloomberg, Getty Locations: U.S, megaprojects, China, Eaton, Corning, Coeur D'Alene, Albemarle, ALB, Novo, New York

☆ When Tesla shares rise — these 7 stocks have tended to rise too, according to recent history
▼ + stars: | 2024-04-24 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

Seven stocks in the S & P 500 tend to rise alongside Tesla shares, according to an analysis of recent data by CNBC Pro . The share price performances of these S & P 500 stocks were highly correlated to Tesla's last month. However, unlike Tesla's more than 30% plunge this year, these stocks have either remained flat or have relatively modest negative returns. A correlation of zero would indicate no statistical link between the EV automaker's stock and the share price of the seven companies. The consensus upside potential for the stocks listed above was derived from FactSet's poll of analysts covering each stock.

Persons: Elon Musk, weathers, — CNBC's Lora Kolodny Organizations: CNBC Pro, Juniper Networks, Seagate Technology, Tyler Technologies, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, IDEXX Laboratories, EV, CNBC Locations: U.S, lockstep

☆ Watch for potential wave of share splits as the average price of S&P 500 stock hits $160, says Strategas
▼ + stars: | 2024-03-26 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

The market may see a new wave of stock splits, creating another growth catalyst for a market that wants to keep rallying, according to Strategas. The median gain of a stock 65 days post-split is 4.1%, compared to the S & P 500's median 2.7% gain during the same period. Stock splits do not change anything fundamentally about the company, but they generally make shares more attractive to the retail trader because of lower prices. Here are the highest-priced stocks in the S & P 500 that Strategas thinks investors could benefit from if they split. Another name on the list, pharmaceutical giant Eli Lilly , last announced a 2-for-1 stock split in September 1997.

Persons: Jason Trennert, Trennert, Strategas, Jensen Huang, CNBC's Jim Cramer, Eli Lilly Organizations: Micro Computer, Nvidia, Broadcom, Costco Wholesale

☆ A 17-year-old took home $250,000 for his award-winning discovery in computer 'brains' that could make AI smarter and safer
▼ + stars: | 2024-03-15 | by ( Jenny Mcgrath | ) www.businessinsider.com time to read: +5 min

Read previewAchyuta Rajaram won this year's Regeneron Science Talent Search $250,000 top prize for his work on making machine learning more efficient and safer. Beating out 2,000 competitorsParticipation in Regeneron Science Talent Search has grown and shrunk over the years, reaching its peak in the late 1960s during the Apollo missions. Achyuta Rajaram said he was shocked to take home the top prize at the Regeneron Science Talent Search. AdvertisementRajaram plans to continue studying computer science at MIT in the fall. His advice to anyone who wants to apply for the Regeneron Science Talent Search is to "be really, really curious about everything."

Persons: —, Achyuta Rajaram, Rajaram, Maya Ajmera, Ajmera, Chris Ayers, McArthur Organizations: Service, Society for Science, Business, Phillips Exeter Academy, Apollo, McArthur Fellows, MIT, Regeneron

☆ Calls of the Day: Regeneron, Thermo Fisher, Darden Restaurants and Nucor
▼ + stars: | 2024-03-13 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCalls of the Day: Regeneron, Thermo Fisher, Darden Restaurants and NucorThe Investment Committee debate the latest calls of the day on a number of stocks.

Organizations: Fisher, Darden

☆ Here are Tuesday's biggest analyst calls: Apple, Tesla, Coinbase, Sony, Oracle, FedEx, Nike, Carvana & more
▼ + stars: | 2024-03-12 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

"We initiate coverage on Regeneron with an Outperform rating and $1,125 price target." Canaccord reiterates MicroStrategy as buy Canaccord raised its price target on the crypto company to $1,810 per share from $975. "We are initiating coverage of The New York Times with a Buy rating and a $52 target price. "DG – Upgrading to Neutral Raising Price Target to $158." "We are initiating coverage of Central Garden & Pet ( CENT) with a BUY rating and $52 price target."

Persons: Bernstein, Morgan Stanley, Tesla, it's, optionality, Canaccord, Goldman Sachs, PDD, Goldman, Jefferies, underperform Jefferies, Raymond James, underperform Raymond James, Argus, Evercore, William Blair, Goldman Sacks Organizations: Citi, New York Times, Nike, JPMorgan, RBC, Bank of America, Apple, Oracle, Central, FedEx, Macquarie, Sony Locations: China

☆ Trade Tracker: Amy Raskin trims Berkshire
▼ + stars: | 2024-03-11 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTrade Tracker: Amy Raskin trims BerkshireAmy Raskin, Chevy Chase Trust CIO, joins CNBC's 'Halftime Report' to explain why she's buying American Express, Natera, Accenture and trimming Berkshire, Costco Vertex Pharma and Regeneron.

Persons: Amy Raskin Organizations: Chevy Chase Trust, American Express, Accenture, Costco Vertex Pharma Locations: Berkshire

☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
▼ + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.

Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly

☆ This week will make it clearer if the Fed will cut interest rates in March
▼ + stars: | 2024-01-28 | by ( Bryan Mena | ) edition.cnn.com time to read: +11 min

Washington, DC CNN —A slew of economic news this week will make it much clearer if the Federal Reserve will cut interest rates in March. The Labor Department is due to release four crucial assessments of America’s job market, gauging labor demand, wage growth, productivity and hiring. Wages and the Fed on Wednesday: The day after, the Labor Department releases its Employment Cost Index for the fourth quarter, a comprehensive measure of employers’ labor costs. The US Labor Department releases December data on job openings, quits, hires and layoffs. The US Labor Department releases its Employment Cost Index for the fourth quarter.

Persons: that’s, ”, Christian Scherrmann, Jerome Powell, ” Michael Feroli, “, ” Feroli, Powell, Alicia Wallace, Joe Brusuelas, Jerome Powell’s Organizations: CNN Business, Bell, DC CNN, Federal Reserve, Labor Department, DWS, Labor, Survey, Fed, Employers, PCE, Federal, Commerce Department, RSM, Whirlpool, Microsoft, UBS, HCA Healthcare, General Motors, Cleveland Cliffs, Mondelez International, JetBlue Airways, Global, US Labor Department, Board, National Bureau of Statistics, Novo Nordisk, Mastercard, Novartis, Boeing, ADP, Nasdaq, Nomura Holdings, Apple, Shell, Honeywell, Deutsche Bank, Clorox, Quest Diagnostics, United States Steel, Bank of England, P Global, Institute for Supply Management, Exxon Mobil, AbbVie, Regeneron Pharmaceuticals, University of Michigan Locations: Washington, Marathon, Cleveland, Chevron

☆ 10 of our stocks report earnings next week. Here's what we want to see from each
▼ + stars: | 2024-01-27 | by ( Zev Fima | ) www.cnbc.com time to read: +16 min

All three major averages posted gains for the third consecutive week, lifted by solid quarterly earnings and positive economic data. Earnings season ramps up next week, with five of the Super Six mega-cap stocks delivering results. Employment numbers are the most important economic data, with Friday's January nonfarm payrolls report carrying the most weight. The January ISM Manufacturing report on Thursday and December's factory orders report Friday are expected to show the sector still in contraction mode. But earnings and commentary this week from peer Sartorious made us encouraged about a return to growth in 2024.

Persons: nonfarm, December's, Sartorious, We've, Stanley Black, Decker, We're, We'd, Royal Philips, Crane, Woodward, ServisFirst, Cadence Bancorporation, CADE, Johnson, Phillips, Avery Dennison, Columbus McKinnon, Robinson, SIRI, Cardinal Health, Parker, DOV, Pitney Bowes, Ferrari N.V, CSW, COLM, W.W, Grainger, Dwight Co, Jim Cramer's, Jim Cramer, Jim, Tim Cook, Justin Sullivan Organizations: Gross, Procter, Gamble, Gillette, Super, Consumer, JPM Healthcare, Amazon, Microsoft, Honeywell, Aerospace, Solutions, Apple Watch, Masimo, Vision Pro, Franklin Resources, Resource Partners, Bank of Marin Bancorp, Bank7 Corp, Pacific Premier Bancorp Inc, Provident Financial Holdings, Dynex, Cliffs Inc, Nucor Corp, Whirlpool Corp, F5 Networks, Capital Southwest Corp, Harbors Investment Corp, Crane Co, Payne, Equity, Heartland Financial, Cadence, FinWise Bancorp, Five Star Bancorp, PotlatchDeltic Corporation, Sanmina Corporation, Pfizer, General Motors Corp, United Parcel Service, JetBlue Airways Corporation, Smith Corp, Marathon Petroleum Corp, HCA Healthcare, Oshkosh Corporation, SYSCO Corp, Danaher Corp, Johnson Controls, M.D.C . Holdings, Commvault Systems Inc, Hope Bancorp, Hubbell Incorporated, Malibu Boats, Polaris Industries, Inc, Camden National Corp, Cambridge Bancorp, Microsoft Corp, Starbucks Corp, Devices, Electronic Arts Inc, Juniper Networks, Stryker Corp, Lending, Canadian, Canadian Pacific Kansas City Limited, Mondelez, Chubb Corporation, Modine Manufacturing, Partners, Management, Hawaiian Holdings, Manhattan Associates, Unum Group, UNM, Axos, Enova, Boston Properties, Boeing Co, Novo Nordisk, Mastercard Inc, Roper Technologies, Boston Scientific Corporation, MarketAxess Holdings, Fisher, Aptiv PLC, Hess Corp, Nasdaq, United Microelectronics Corp, Rockwell Automation, Teva Pharmaceutical Industries, Ltd, Avery, Avery Dennison Corp, Extreme Networks, Otis Worldwide Corporation, OTIS, Columbus, Columbus McKinnon Corp, Central Pacific Financial Corp, Brinker International, Fortive Corporation, Qualcomm, Technology, Metlife, Hanover Insurance, Barn Holdings, CONMED Corporation, DLH Holdings Corp, Meritage Homes Corporation, Honeywell International, Eaton Corp, Altria, Royal Caribbean Cruises Ltd, Merck, Co, Enterprise Products Partners, Dorian LPG, SiriusXM Holdings, Cardinal, Hannifin Corporation, Allegheny Technologies Incorporated, Tractor Supply Company, Trane Technologies, Dover Corp, Huntington Ingalls Industries, Brunswick Corporation, Dickinson, Canada Goose Holdings, Kirby Corp, WEC Energy Group, WestRock Company, Allegro MicroSystems, Ball Corporation, Broadridge Financial, BrightSphere Investment Group, CMS Energy Corp, Lancaster Colony Corp, Rogers Communications Inc, Sanofi, Apple, Atlassian Corporation, United States Steel Corp, Corp, Adtalem Global, Homes, DXC Technology Company, Eastman Chemical Company, Gen, Post Holdings, America, Columbia Sportswear Company, Exxon Mobil Corp, Chevron Corporation, Myers Squibb Co, CIGNA Corp, Regeneron Pharmaceuticals, Charter Communications, AON, Cboe, Dwight, Banco Santander, Jim Cramer's Charitable, CNBC, Apple Vision, Getty Locations: China, East, United States, Europe, Cleveland, Alexandria, California, Corning, Canadian Pacific, Teradyne, TER, Novo, Hanover, PBI, Skechers U.S.A, Bristol, Chile

Gene therapy has allowed several children born with inherited deafness to hear. Globally, 34 million children have deafness or hearing loss, and genes are responsible for up to 60% of cases. Hereditary deafness is the latest condition scientists are targeting with gene therapy, which is already approved to treat illnesses such as sickle cell disease and severe hemophilia. Also, some people consider gene therapy for deafness ethically problematic. "This is real proof showing gene therapy is working,” Chen said.

Persons: ”, Zheng, Yi Chen, Dr, Yilai Shu, Chen, Eli Lilly, Akouos, he's, John Germiller, ” Germiller, “, Lawrence Lustig, Teresa Blankmeyer Burke, ” Chen Organizations: Children's Hospital of Philadelphia, Fudan University, Shanghai Refreshgene Therapeutics, Regeneron Pharmaceuticals, Decibel Therapeutics, Columbia, Gallaudet University, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: China, Shanghai, Philadelphia, Spain

☆ Cramer lists his major themes for the market in 2024
▼ + stars: | 2024-01-17 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

CNBC's Jim Cramer on Wednesday reviewed what he thinks will be major themes on the market in 2024, including strength in the health-care sector due to weight loss drugs and success for mergers and acquisitions. With the major indexes declining on Wednesday, Cramer thought it would be helpful to tell investors what broader market themes they can reference on down days. And if you understand the themes behind them, you won't get shaken out by a bad tape—you'll use it to your advantage," Cramer said. He wondered whether other stocks would join the ranks of the "Magnificent Seven," but conceded that any contenders will be involved with artificial intelligence. "I'll have a lot more themes as the year goes on, because I'm not constrained by the calendar," he said.

Persons: CNBC's Jim Cramer, Cramer, Tesla, Elon Musk's, Becton Dickinson, Eli Lilly, I'm Organizations: Abbott Labs Locations: China

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ Sanofi looks to widen Dupixent use to treat 'smoker's lung' after second trial win
▼ + stars: | 2023-11-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. REUTERS/Gonzalo Fuentes/File photo Acquire Licensing RightsNov 27 (Reuters) - Sanofi (SASY.PA) plans to seek U.S. approval for it best-selling anti-inflammatory drug Dupixent to be used in the treatment of "smoker's lung", also known as COPD, after a second large trial showed significant benefits. The company had embarked on a second trial to bolster the statistical reliability of the read-outs. Details of the second trial would be presented at an as yet undisclosed medical conference, Sanofi added. The company has been discussing with major watchdogs across the world whether the BOREAS results were substantial enough to support a regulatory review and what role the second trial would play in reviews.

Persons: Sanofi, Gonzalo Fuentes, BOREAS, Ludwig Burger, Tassilo Hummel, Edwina Gibbs Organizations: Sanofi, Polyclonals, REUTERS, Food and Drug Administration, Thomson Locations: Lyon, France

☆ Here are Friday's biggest analyst calls: Nvidia, Apple, Amazon, Uber, Coinbase, Carvana, Starbucks & more
▼ + stars: | 2023-11-03 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Here are Friday biggest calls on Wall Street: Morgan Stanley reiterates Apple as overweight Morgan Stanley said it's standing by Apple shares after its earnings report on Thursday. Berenberg downgrades Estee Lauder to hold from buy Berenberg downgraded the stock after its disappointing earnings report earlier this week. Morgan Stanley reiterates Carvana as underweight Morgan Stanley said it's sticking with its underweight rating on the stock after its earnings report on Thursday. " Evercore ISI downgrades Fortinet to in line from outperform Evercore downgraded the cybersecurity company after its earnings report. JPMorgan reiterates Starbucks as overweight JPMorgan said the coffee giant is "still one to buy" after its earnings report on Thursday. "

Persons: Morgan Stanley, Apple, it's, downgrades Estee Lauder, Estée Lauder, Piper Sandler, Piper, OMCL, Key, Wolfe, Mizuho, C27E, JPMorgan downgrades, Papa John's, PZZA, Raymond James, Carvana, CVNA, Redburn, JPMorgan, SBUX, Guggenheim, GNRC Organizations: Apple, DOJ, Uber, Deutsche Bank, Molson Coors, Deutsche, HSBC, Moderna, Nvidia, Mizuho, JPMorgan, JPMorgan downgrades Fox, FOX, Barclays, Retail, Evercore, billings, Guggenheim, Citi, Cedar, Flags, ~$

☆ Sanofi loses $21 bln in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +6 min

Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability". EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target. CONSUMER STAND-ALONECEO Hudson said the core innovative drugs business had improved enough to soon do without the more predictable cash flows from consumer products. The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. The timing of the potential consumer listing, which Sanofi said would be in the fourth quarter of 2024 or later, would be set to maximize shareholder value.

Persons: Hudson, Sanofi, drugmaker, Paul Hudson, Terence McManus, Johnson, we've, Gonzalo Fuentes, Roche, Dupixent, Ludwig Burger, Sherry Jacob, Phillips, Mark Potter, Sharon Singleton Organizations: Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer, Bayer, Polyclonals, REUTERS, Provention, Merck & Co, Thomson Locations: France, Bellevue, Lyon, Paris

☆ These stocks are trying to solve a major shortcoming of weight loss drugs: Shrinking muscle mass
▼ + stars: | 2023-10-22 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

One of the downsides of taking new anti-obesity medications is that patients tend to lose lean muscle mass along with body fat. "This is a major shortcoming in terms of not just quality of life for the patients who have to lose lean muscle mass, but there's actually room to improve on the weight loss and there [are] other metabolic benefits to improving your lean muscle mass ... [including] you might have better durability of weight loss." The drug is being tested in a phase 2b study alongside semaglutide to protect against loss of muscle mass. Until then, patients will need to watch what they eat and focus on exercise just as they would on any other weight loss regimen. When that occurs, muscle loss will be an even bigger issue than it is now.

Persons: Piper Sandler, Allison Bratzel, there's, Bratzel, Versanis, Eli Lilly, Eli Lilly's Mounjaro, they're, Lydia Alexander, Alexander, Sandler's Bratzel, incretins, Biohaven, Nestle, Ulf Mark Schneider, Jeff Jonas, Jonas, Stephens, Jim Salera, Atkins, Morgan Stanley, — CNBC's Michael Bloom Organizations: Wall, Nordisk's Ozempic, Obesity Medicine Association, Bristol Myers Squibb, Nestle, Gabelli, Quest, Foods Locations: Swiss

☆ Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales
▼ + stars: | 2023-10-19 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

Quarterly sales came in at 14.3 billion Swiss francs ($15.9 billion), the Swiss drugs and diagnostics maker said in a statement, broadly in line with analyst estimates. A high-dose version of Eylea for less frequent injections won U.S. approval in August, creating doubt among analysts that a string of forecast-beating Vabysmo sales can continue. CEO Thomas Schinecker - who is keen to restore Roche's drug development record - said he was looking to acquire drug assets in all stages of development but that there was no rush. He pointed to 10% sales growth during the quarter, excluding currency headwinds and the slump in COVID sales. However, it predicted a less pronounced decline in sales of COVID-19 products of about 4.5 billion Swiss francs, from a previous estimate of a drop of 5 billion francs.

Persons: drugmaker Roche, Arnd, Roche, Regeneron, Thomas Schinecker, Schinecker, Ludwig Burger, Friederike Heine, Elaine Hardcastle Organizations: REUTERS, Bayer, Thomson Locations: Basel, Switzerland, COVID, Swiss

Scientists are setting out to collect genetic material from 500,000 people of African ancestry to create what they believe will be the world’s largest database of genomic information from the population. The initiative was launched Wednesday by Meharry Medical College in Nashville, Tennessee, as well as Regeneron Genetics Center, AstraZeneca, Novo Nordisk and Roche. Organizers said there’s a clear need for the project, pointing to research showing that less than 2% of genetic information being studied today comes from people of African ancestry. Each of the pharmaceutical companies involved intends to contribute $20 million toward the genetic and educational parts of the effort. ___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group.

Persons: Meharry, ”, Anil Shanker, Lyndon Mitnaul Organizations: Meharry Medical College, Genetics Center, AstraZeneca, Novo Nordisk, Roche, Genomics Institute, Organizers, Regeneron Genetics, University of Zambia, Project, Genetics, Corporate, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: Nashville , Tennessee, Americas, Asia, Europe, Nashville, U.S, Africa, Meharry

☆ Award-winning actor, director Debbie Allen's daily habits for staying healthy at 73, including climbing the Santa Monica Stairs
▼ + stars: | 2023-09-11 | by ( Renée Onque | ) www.cnbc.com time to read: +1 min

Debbie Allen is a legend in her own right for her various talents like acting, dancing, choreographing, directing and producing. Diet is extremely important to Allen because she has a history of diabetes in her family and is pre-diabetic. Thankfully, Allen has great examples in her family on how to approach health and wellness. "Part of mom's routine — she lives with me and my husband — is going to regular visits to the eye doctor," says Allen. "I'm pre-diabetic and so I'm one of those who could be at risk [of certain retinal diseases].

Persons: Debbie Allen, Deborah Kaye Allen, Allen, retinopathy, Phylicia Rashad, —, I'm Organizations: CNBC, Prevent

☆ BEA Foundation poll shows 78% of Americans support active diversity efforts, says CEO
▼ + stars: | 2023-09-06 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBEA Foundation poll shows 78% of Americans support active diversity efforts, says CEOCharles Phillips, Recognize co-founder and managing partner, and Dr. Tony Coles, The Black Economic Alliance CEO and Regeneron board member, join 'Squawk Box' to discuss a recent poll on diversity, equity and inclusion efforts in corporate America, if DEI efforts have been categorized with the word 'woke', and what the public wants companies to do.

Persons: Charles Phillips, Tony Coles Organizations: BEA, Black Economic Alliance Locations: America

☆ Covid-19 has changed and so has our immunity. Here’s how to think about risk from the virus now
▼ + stars: | 2023-08-28 | by ( Brenda Goodman | ) edition.cnn.com time to read: +19 min

So if people are less likely to be hospitalized or die from a Covid-19 infection now, has the danger passed? Through genetic bad luck, some people may just be at higher risk of serious reactions to Covid-19 infections, and they probably wouldn’t know it. Researchers defined it as any new or continuing symptoms more than 90 days after a Covid-19 infection. Based on his experience treating long Covid patients, Griffin said that the percentage reported in the Australian paper seems high. Earlier in the pandemic, pediatric infectious disease specialists were on the lookout for a rare complication of Covid-19 infection in kids called multisystem inflammatory syndrome in children, or MIS-C.MIS-C starts two to six weeks after a Covid-19 infection.

Persons: CNN —, we’ve, aren’t, Good, ”, Megan Ranney, Covid, ” Ranney, that’s, Evusheld, haven’t, you’ve, they’re, They’re, Mandy Cohen, It’s, –, Jesse Bloom, Daniel Griffin, it’s ‘, Griffin, “, Peter Chin, Chin, Hong, Nathaniel Hendrix, Hendrix, it’s, hasn’t, she’s, Kristin Englund, shouldn’t, Dr, Sanjay Gupta, “ It’s, Ellie Murray, ” Murray Organizations: CNN, US Centers for Disease Control, Yale School of Public Health, Covid, National Institutes of Health, FDA, US Department of Health, Human Services, CDC, Fred Hutchinson Cancer Center, HHS, Columbia University, University of California, Census Bureau, Nature Medicine, American Board of Family Medicine, Nature, Veterans Affairs, Cleveland Clinic, CNN Health, Boston University School of Public Health Locations: South Africa, Botswana, United States, China, Seattle, Israel, Denmark, United Kingdom, Portugal, US, Switzerland, Thailand, Australia, San Francisco, Ohio

☆ US govt awards $1.4 bln for development of new COVID therapies, vaccines
▼ + stars: | 2023-08-22 | by ( ) www.reuters.com time to read: +1 min

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsCompanies Regeneron Pharmaceuticals Inc FollowAug 22 (Reuters) - The U.S. government said on Tuesday it had awarded $1.4 billion for the development of new therapies and vaccines against COVID-19, including a $326 million contract with Regeneron Pharmaceuticals (REGN.O) for a next-generation antibody therapy for prevention of infections. The funding to Regeneron is a part of a $5 billion initiative dubbed "Project NextGen" by the U.S. Department of Health and Human Services (HHS). The funding also includes $1 billion for four mid-stage clinical trials of new COVID vaccines, and $100 million to Global Health Investment Corp - a non-profit organization that invests in new technologies that will accelerate responses to diseases. Reporting by Pratik Jain in Bengaluru; Editing by Maju SamuelOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Regeneron, Pratik Jain, Maju Samuel Organizations: Regeneron Pharmaceuticals, REUTERS, U.S, COVID, U.S . Department of Health, Human Services, U.S . Food, Drug Administration, Omicron, Global Health Investment Corp, Thomson Locations: Westchester, Tarrytown , New York, U.S, Bengaluru

☆ This biotech name is one of Jim Cramer's favorite stocks and he thinks it can go even higher
▼ + stars: | 2023-08-21 | by ( Morgan Chittum | ) www.cnbc.com time to read: 1 min

Regeneron Pharmaceuticals (REGN) rose Monday after the Food and Drug Administration approved a higher-dose formulation of Eylea, the company's macular degeneration treatment. If you like this story, sign up for Jim Cramer's Top 10 Morning Thoughts on the Market email newsletter for free. CNBC's Jim Cramer said on "Squawk on the Street" that Regeneron is one of his favorite health-care names, describing Eylea as "a remarkable drug for macular degeneration." "I think being up [11 points] is not enough," Jim said as shares traded $11 higher. The CNBC Investing Club with Jim Cramer doesn't own Regeneron.

Persons: Jim Cramer's, CNBC's Jim Cramer, Leonard Schleifer's, Jim, Jim Cramer doesn't, Eli Lilly Organizations: Regeneron Pharmaceuticals, Food and Drug Administration, CNBC

Search resuls for: "Regeneron"

25 mentions found